Lofarma S.p.A.
Lofarma S.p.A. is a family-owned Italian pharmaceutical company founded in 1945 that develops and manufactures sublingual allergen immunotherapy, prick-test diagnostics, and OTC allergy prevention products (anti-dust mite bedding, ear care) for allergic patients and prescribing allergists across more than 20 countries.
- Company typePrivate
- Founded1945
- HeadquartersMilan, Italy
- Headcount51–100
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Lofarma S.p.A. does
Lofarma S.p.A. is a privately held Italian pharmaceutical company founded in 1945 and headquartered in Milan, specializing in the diagnosis and treatment of allergic respiratory diseases. The company has been controlled by the Vaglio family since 1952, with Domitilla Vaglio assuming leadership in 2022 alongside President Rubens Vaglio. Its core offering is sublingual allergen immunotherapy — described as the only sublingual therapy globally using carbamylated monomeric allergoid technology — supported by prick-test diagnostics and a proprietary Superallergoid vaccine formula. Production is anchored in an AIFA-validated manufacturing facility that includes an in-house acarology (mite breeding) laboratory for direct allergen research.
Lofarma generates revenue through two principal streams. The first is prescription immunotherapy (60% of domestic turnover), distributed via dedicated medical sales representatives (informatori scientifici) targeting allergists, pulmonologists, dermatologists, and pediatricians, with pricing not publicly disclosed and an annual recurring treatment cycle. The second is consumer healthcare sold directly through the company's e-commerce platform, including Aclobed and Aclobed piuma anti-dust mite bedding (€17–€165.50 per unit), Otinova ear spray (€18.30 for 15ml), and Otovent ear pressure devices (€12.00). Geographic mix is 60% Italy and 40% international, served through wholly-owned subsidiaries in Spain (Lofarma Iberica) and Portugal (Lofarma Lusitana) plus a distribution partner network spanning more than 20 countries.
The company is positioned within a narrow allergology niche and sustains its specialty through long-running physician education programs — Lofarma Academy, the Notiziario Allergologico scientific journal (44th volume), and school-based allergy awareness initiatives — alongside partnerships with bodies such as SIAIP (Italian Society of Pediatric Allergy and Immunology). Its stated growth trajectory is 25% over four years with an 8% increase in 2025, reflecting steady but decelerating expansion in a category where its proprietary carbamylated monomeric allergoid formulation constitutes a defensible technical moat.
Lofarma S.p.A. firmographics
Firmographics- Name
- Lofarma S.p.A.
- Legal name
- Lofarma S.p.A.
- Website
- https://lofarma.it
- Company type
- Private
- Founded year
- 1945
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Lofarma S.p.A. is a family-owned Italian pharmaceutical company founded in 1945 that develops and manufactures sublingual allergen immunotherapy, prick-test diagnostics, and OTC allergy prevention products (anti-dust mite bedding, ear care) for allergic patients and prescribing allergists across more than 20 countries.
- Ownership category
- akta.pro rank
Lofarma S.p.A. industry classification
Industry- Product category
- Allergen Immunotherapy Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
- akta.pro secondary industries
- Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
Keywords
Where Lofarma S.p.A. is headquartered
LocationHeadquarters
- HQ city
- Milan
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
Lofarma S.p.A. business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Allergen Immunotherapy Products: Prescription-only sublingual allergenic vaccines for treating respiratory allergies including dust mites, pollen, cat epithelium, and other allergens. Generated 60% of turnover domestically.
- Consumer Healthcare Products: Direct-to-consumer e-commerce sales of anti-dust mite bedding (Aclobed, Aclobed piuma), ear care products (Otinova, Otovent), and nickel allergy treatments.
- Diagnostics: Prick test diagnostic tools for allergy diagnosis, sold to healthcare providers and specialists.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Aclobed anti-dust mite bedding covers - various sizes |
| Unit Pricing | Pay-as-you-go | Aclobed piuma premium anti-dust mite bedding |
| Unit Pricing | Pay-as-you-go | Otinova ear spray - 15ml (150 doses) |
| Unit Pricing | Pay-as-you-go | Otovent latex balloon for ear pressure |
| Subscription | Annual | Allergen immunotherapy (prescription-only) |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels6 records
Lofarma S.p.A. product offering
Product offeringCore offering
Lofarma S.p.A. develops, manufactures, and commercializes prescription allergen-specific sublingual immunotherapy products using its proprietary carbamylated monomeric allergoid technology, alongside prick-test diagnostics and a consumer line of anti-dust mite bedding, ear care, and nickel allergy products. The company sells prescription therapies through physician specialists and medical sales representatives, and consumer healthcare products directly via e-commerce and international subsidiaries.
Product overview
Lofarma S.p.A. is an Italian pharmaceutical company specializing in allergy diagnosis and treatment since 1945. The company offers a portfolio of products comprising two core offerings: (1) Allergen Immunotherapy — the only sublingual therapy with carbamylated monomeric allergoid for treating allergic respiratory diseases, and (2) Diagnostics using the prick test technique. Supporting these core products are several specialized add-on modules: Aclobed and Aclobed piuma (anti-dust mite mattress/pillow covers in polypropylene and polyester respectively), Otinova® (ear spray for ear canal inflammation), and Otovent Lofarma (latex balloon for middle ear pressure balancing). The company also publishes the Notiziario Allergologico, a scientific journal for allergology professionals. The product portfolio addresses allergies including dust mites, cat epithelium, grass pollen, pellitory, olive pollen, birch pollen, ragweed, mugwort, and nickel.
Differentiator
Problem solved
Functional benefit
Products and services
- Allergen Immunotherapy (Sublingual Allergenic Vaccines)
- Allergy Diagnostics (Prick Test)
- Aclobed Anti-Dust Mite Bedding Covers
- Aclobed Piuma Premium Anti-Dust Mite Bedding
- Otinova Ear Spray
- Otovent Lofarma Ear Pressure Balloon
Quantifiable outcome
- 25% global growth over four years with 8% increase in 2025
Companies that use Lofarma S.p.A.
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles2 records
Lofarma S.p.A. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Lofarma S.p.A. partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Lofarma IbericacoreSpanish subsidiary of Lofarma managing distribution and commercial operations in Spain. Contact: [email protected]. Established as the first international subsidiary of Lofarma.
- Lofarma Lusitana LdacorePortuguese subsidiary of Lofarma managing distribution and commercial operations in Portugal. Contact: [email protected]. Originally established as Lofarma Luisitana Limitada in late 1980s.
- Paesel-LoreiminorGerman distributor partner for Lofarma products. Contact: [email protected].
- SIAIP (Società Italiana di Allergologia e Immunologia Pediatrica)coreItalian Society of Pediatric Allergy and Immunology. Lofarma partners with SIAIP for educational initiatives including the 'Premio Paolo Falagiani' award for young physicians and the 'Un'allergia per amica' school education project. SIAIP provides scientific patronage and expertise.
Scale indicators5 records
Recent moves9 records
Expansion highlights5 records
Lofarma S.p.A. competitors and assessment
Company assessmentDirect peers
- Stallergenes Greer: A global leader in allergen immunotherapy (sublingual and subcutaneous) backed by Eurazeo, headquartered in France. Directly competes with Lofarma across pollen, mite, and epithelia SLIT tablets and drops in the same specialist prescriber channel.
- ALK-Abelló: Danish-listed global leader in allergy immunotherapy with a broad SLIT tablet portfolio (e.g., ACARIZAX, ITULAZAX). Competes head-on with Lofarma in the prescription sublingual segment and is many times its size.
- Allergy Therapeutics: UK-based specialty pharma developing subcutaneous and sublingual allergy immunotherapies with a focus on modified allergen extracts. Direct competitor in the European AIT market, including in Italy and other markets where Lofarma is present.
- HAL Allergy Group: Dutch-German allergen immunotherapy company offering subcutaneous and sublingual therapies plus diagnostics. Direct peer selling in overlapping European specialist channels with comparable product structure.
- Leti Pharma: Spanish biotechnology company specializing in allergy diagnosis and immunotherapy, with strong presence in Spain and Latin America. Overlaps with Lofarma's Iberica subsidiary and competes across prick-test diagnostics and SLIT/SCIT products.
- Roxall Medizin: German specialty pharma focused on allergen immunotherapy and diagnostics, distributing in the DACH region. Comparable mid-sized European AIT peer with similar product mix (allergen extracts, diagnostics).
Emerging players
- Biomay AG: Austrian biotech developing recombinant and peptide-based allergen immunotherapies. Adjacent / emerging peer whose next-generation recombinant approach could compete with traditional allergoid-based SLIT over time.
Broad incumbents
- Sanofi: Global pharmaceutical major with a significant allergy/respiratory franchise (e.g., Dupixent) and broad distribution. Overlaps with Lofarma in respiratory allergy but operates at vastly larger scale and is not specialized in allergen-specific immunotherapy.
- GSK: Global pharma with a large respiratory and allergy portfolio (e.g., Flonase, Nucala). Broad incumbent serving similar patients but with focus on symptomatic and biologic treatments rather than allergen-specific SLIT.
- Thermo Fisher Scientific (Phadia - Allergy Diagnostics): Owns the ImmunoCAP allergy diagnostics platform (via Phadia), the dominant in-vitro allergy testing franchise. Comparable to Lofarma's prick-test diagnostics business but at global scale, with both competing for the same specialist diagnostic budgets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Lofarma S.p.A. social profiles
Digital presenceLofarma S.p.A. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lofarma S.p.A. leadership team
Management profileNumber of profiles
Profiles4 records
Lofarma S.p.A. subsidiaries and ownership
Company hierarchySubsidiaries2 records
Lofarma S.p.A. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lofarma S.p.A. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lofarma S.p.A.
What does Lofarma S.p.A. do?
Lofarma S.p.A. develops, manufactures, and commercializes prescription allergen-specific sublingual immunotherapy products using its proprietary carbamylated monomeric allergoid technology, alongside prick-test diagnostics and a consumer line of anti-dust mite bedding, ear care, and nickel allergy products. The company sells prescription therapies through physician specialists and medical sales representatives, and consumer healthcare products directly via e-commerce and international subsidiaries.
Is Lofarma S.p.A. a public or private company?
Lofarma S.p.A. is a private company. It is classified as family owned and is currently operating.
When was Lofarma S.p.A. founded?
Lofarma S.p.A. was founded in 1945. It employs 51 to 100 people.
Where is Lofarma S.p.A. based?
Lofarma S.p.A. is headquartered in Milan, Italy, in the Europe region.
How does Lofarma S.p.A. make money?
Three revenue lines are on record. Allergen Immunotherapy Products are the primary driver. The others are consumer Healthcare Products and diagnostics.
Who are Lofarma S.p.A.'s main competitors?
Direct peers on record are Stallergenes Greer, ALK-Abelló, Allergy Therapeutics, HAL Allergy Group, Leti Pharma and Roxall Medizin. Biomay AG is listed as an emerging player. Broad incumbents are Sanofi, GSK and Thermo Fisher Scientific (Phadia - Allergy Diagnostics).
Does Lofarma S.p.A. have an API?
No public API is recorded for Lofarma S.p.A..
What industry is Lofarma S.p.A. in?
Lofarma S.p.A.'s product category is Allergen Immunotherapy Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals, with a secondary code of HLAAAEAI, Allergy Immunotherapy Biologics (allergen extracts, desensitization). Its NAICS code is 325412 and its SIC code is 2834.